Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311148) titled 'A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and Older' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Guangzhou Patronus Biotech Co., Ltd.
Condition:
Herpes Zoster (HZ)
Shingles
VZV
Recombinant Zoster Vaccine
Intervention:
Biological: Low dose antigen and low dose adjuvant of LYB004
Biological: Low dose antigen and high dose adjuvant of LYB004...